Turning ETEC Vaccine Development into Real Impact – Together with EDCTP
Developing a vaccine against ETEC in young children has long been a global health challenge. We are now closer than ever to changing that.
At Scandinavian Biopharma, we are advancing what could become the world’s first vaccine to protect young children against ETEC—a major cause of diarrhoeal disease affecting millions globally. The progress highlighted by EDCTP reflects years of focused execution, strong partnerships, and a shared commitment to delivering impact where it matters most.
EDCTP’s support shows what long-term collaboration can achieve: strong science, local capacity building, and real momentum toward a vaccine with global impact. Now, we move into the next phase. Together, we are taking important steps toward reducing the burden of childhood diarrhoeal disease.
